Description
Retatrutide (also designated LY-3437943) is a synthetic, 42-amino-acid peptide developed by Eli Lilly and Company and classified as a triple hormone receptor agonist [7]. Its defining pharmacological feature is the simultaneous activation of three distinct receptor systems: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor (GCGR) [2]. This multi-receptor profile distinguishes it from earlier incretin-based peptides that target only one or two of these pathways [1].
The peptide incorporates a fatty acid side-chain modification that promotes reversible binding to serum albumin. Researchers employ this albumin-binding strategy to reduce the rate of enzymatic degradation, extending the molecule's stability in biological matrices. The lyophilized form in which it is supplied helps preserve this structural integrity during storage and handling.
Retatrutide's concurrent engagement of GLP-1, GIP, and glucagon signaling pathways makes it a valuable tool for investigating metabolic receptor pharmacology and the downstream signaling consequences of multi-receptor co-activation [3]. Preclinical animal studies have explored its effects on gastric motility, food intake behavior, and body composition, while the compound's incretin agonist activity has also drawn interest in the context of body composition research, including the relationship between weight loss pharmacology and lean mass retention [4]. Researchers use retatrutide as a molecular probe to interrogate how simultaneous activation of these three axes influences metabolic signaling networks.
Kilonova Peptides supplies retatrutide as a lyophilized powder, batch-verified by HPLC for purity and confirmed by mass spectrometry for molecular identity, with certificates of analysis available for each lot.
References
[1] Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care, 2024. https://pubmed.ncbi.nlm.nih.gov/38843460/
[2] Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England Journal of Medicine, 2023. https://pubmed.ncbi.nlm.nih.gov/37366315/
[3] Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules, 2025. https://pubmed.ncbi.nlm.nih.gov/40563436/
[4] Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care, 2024. https://pubmed.ncbi.nlm.nih.gov/38687506/
[7] Retatrutide. Wikipedia. https://en.wikipedia.org/wiki/Retatrutide
